Aflac Net Earnings Plunge 81.5% To $303 Million On Portfolio Sales, Adjusted Profit Slips 8.5%

Investment losses of $1.1 billion swamped the quarter, while adjusted earnings per share slipped 2.4% to $2.43 and the dividend rose again.

Share
Aflac Net Earnings Plunge 81.5% To $303 Million On Portfolio Sales, Adjusted Profit Slips 8.5%

Aflac, which sells supplemental health and life insurance in Japan and the United States, said third-quarter net earnings fell 81.5% to $303 million, from $1.6 billion a year earlier, primarily because of realized losses from repositioning its investment portfolio. Stripping out investment gains and losses, adjusted earnings fell 8.5% to $1.2 billion.

A $1.1 billion investment hit

Net earnings came to $0.61 per diluted share, against $3.08 a year ago. Net investment losses were $1.1 billion, or $2.15 per share, versus gains of $275 million a year earlier. They included $842 million of net losses from sales and redemptions, $146 million of losses on certain derivatives and foreign currency activities, and $102 million of expected credit losses.

The quarter also carried a $51 million, or $0.10 per share, valuation allowance against deferred tax assets tied to tax capital loss carryforwards. Total revenues fell 31.0% to $3.3 billion.

Adjusted earnings per diluted share dropped 2.4% to $2.43. Adjusted earnings benefited from $453 million of reserve remeasurement gains, and the weaker yen cost $0.03 per share.

Japan margin narrows, U.S. widens

Aflac Japan, which sells cancer, medical, nursing care and life insurance, posted a pretax adjusted profit margin of 44.4%, down from 52.2%. Pretax adjusted earnings fell 15.2% in yen terms, which the company tied mainly to higher benefits and smaller reserve remeasurement gains. Japan sales slipped 4.0% to ¥18.8 billion.

Aflac U.S. went the other way. Pretax adjusted earnings rose 31.5% to $493 million, a 27.7% margin against 21.7% a year ago, helped by higher premiums, lower expenses and bigger reserve remeasurement gains. U.S. sales rose 3.5% to $403 million.

CFO Max Brodén's investor update said the company raised its 2026 expected pretax profit margin range for Aflac Japan to 35% to 38%.

Cash returned and a Bermuda reinsurance deal

Aflac returned $1.1 billion to shareholders in the quarter: $804 million of buybacks and $305 million of dividends. The board declared a fourth-quarter dividend of $0.61 per share, marking 44 consecutive years of increases. It is payable December 1 to holders of record on November 18.

During the quarter Aflac Japan ceded about ¥500 billion of cancer insurance reserves, on a Japanese regulatory basis, to its Bermuda affiliate, Aflac Re Bermuda.

Aflac holds its third-quarter earnings call Thursday at 8:00 a.m. ET.

Sources